Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Hims & Hers Health, Inc. Class A Common Stock (NY:HIMS)

28.40 +1.41 (+5.22%)
Streaming Delayed Price Updated: 11:36 AM EDT, Apr 17, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Hims & Hers Health, Inc. Class A Common Stock

< Previous 1 2
...
30 31 32 33 34 35 36 37 38
...
53 54 Next >
News headline image
EXCLUSIVE: Is Super Bowl $7M Ad Cost Worth It? 61% Say No, 18% Say They Looked Up Companies After Last Year's NFL Championship ↗
Benzinga readers pick whether a $7 million Super Bowl cost is worth it for companies and how likely they are to look up a company that may be new to them after the big game. 
Via Benzinga
News headline image
Hims & Hers Health Unusual Options Activity ↗
 
Via Benzinga
News headline image
Super Bowl LIX Commercials: AI, Celebs, Muppets, Warren Buffett-Linked Brand Take The Spotlight ↗
A list of Super Bowl LIX commercials and the celebrities and athletes attached to star in the ads. 
Via Benzinga
Topics Artificial Intelligence
News headline image
Hims & Hers Health Unusual Options Activity For February 03 ↗
 
Via Benzinga
News headline image
Unlocking the Growth Potential of NYSE:HIMS. ↗
A fundamental analysis of (NYSE:HIMS): Is HIMS & HERS HEALTH INC (NYSE:HIMS) suited for growth investing? 
Via Chartmill
News headline image
Is Hims & Hers Health Stock a Buy? ↗
Here's a look into one of healthcare's hottest growth stocks. 
Via The Motley Fool
News headline image
Hims & Hers Health Unusual Options Activity ↗
 
Via Benzinga
News headline image
We Asked Retail Traders About Eli Lilly’s Biggest Post-Q4 Risk — Most Say It’s The Weight-Loss Drug Wars ↗
Lilly’s fiercest competitor in the obesity market is Novo Nordisk, which offers Ozempic and Wegovy. However, rising threats from other players such as Hims & Hers, Amgen, and Viking Therapeutics also... 
Via Stocktwits
News headline image
Hims & Hers Launches Health Collective and Community Member Council
From Hims & Hers
Via Business Wire
News headline image
Hims & Hers to Announce Fourth Quarter and Full Year 2024 Financial Results on February 24, 2025
From Hims & Hers
Via Business Wire
News headline image
Akero Therapeutics, Brinker International And Viavi Are Among Top Mid Cap Gainers Last Week (Jan 27-Jan 31): Are The Others In Your Portfolio? ↗
Check out this week's top-performing mid-cap stocks, including Akero Therapeutics' remarkable 106.57% surge following positive clinical trial results and other companies like Surgery Partners... 
Via Benzinga
News headline image
Why the high growth investor may take a look at NYSE:HIMS. ↗
Unlocking the high Growth Potential of HIMS & HERS HEALTH INC (NYSE:HIMS). 
Via Chartmill
News headline image
Is Hims & Hers Stock in Trouble? ↗
Via The Motley Fool
News headline image
Evaluating NYSE:HIMS for Growth Investment Opportunities. ↗
Is HIMS & HERS HEALTH INC (NYSE:HIMS) suited for growth investing? 
Via Chartmill
News headline image
Ultrasound Weight Loss: GE HealthCare and Novo Nordisk’s Play
GLP-1 drugs have been all the rage for weight loss, but GE Healthcare and Novo Nordisk are working on a non-invasive approach to controlling metabolic functions 
Via MarketBeat
News headline image
8 Health Care Stocks Whale Activity In Today's Session ↗
 
Via Benzinga
News headline image
Hims & Hers Health: A Stock to Trade or Own?
HIMS achieved remarkable growth in 2024 but now faces challenges in 2025, raising the question of whether it suits traders better than long-term investors. 
Via MarketBeat
News headline image
Why Viking Therapeutics Stock Popped, but Novo Nordisk and Hims & Hers Health Dropped Today ↗
Via The Motley Fool
News headline image
Top Growth Picks: 3 Low-Cost Stocks That Could Double in Value
Here are three low-priced stocks you can buy today that are positioned in sector that make them solid choices to double in 2025 
Via MarketBeat
News headline image
What 12 Analyst Ratings Have To Say About Hims & Hers Health ↗
 
Via Benzinga
News headline image
10 Health Care Stocks With Whale Alerts In Today's Session ↗
 
Via Benzinga
News headline image
Hims & Hers Stock Is Poised for a Major Surge in 2025 ↗
The focus is on GLP-1s, but there's more to Hims & Hers than one product. 
Via The Motley Fool
News headline image
What's Going On With Hims & Hers Health Stock? ↗
Hims & Hers reported impressive third-quarter results in November, with earnings of 32 cents per share, far exceeding analyst expectations. 
Via Benzinga
News headline image
Stock Picks 2024 Year In Review ↗
Unlike 2023, 2024 was a very concentrated year, with just a few key large-cap stocks driving much of the index's returns. 
Via Talk Markets
Topics Stocks / Equities
News headline image
Is Hims & Hers Health a Millionaire Maker? ↗
Arguments are piling up for why the company might fail, but the business continues to deliver strong results. 
Via The Motley Fool
News headline image
3 Hot Stocks That Can Double Again in 2025 ↗
Three unlikely winners of 2024 can lead the way in the year ahead. 
Via The Motley Fool
News headline image
Prediction: This Will Be Amazon's Next Big Acquisition ↗
Amazon may be known for its retail and tech chops, but the company has also built a strong operation in the healthcare realm over the last several years. 
Via The Motley Fool
News headline image
10 Health Care Stocks With Whale Alerts In Today's Session ↗
 
Via Benzinga
News headline image
Will The Falling Hims & Hers Stock Price Recover In 2025? ↗
Hims & Hers share price has crashed by over 20% this year after an unfavorable FDA ruling. 
Via Talk Markets
Topics Stocks / Equities
News headline image
Hims & Hers Stock: Growth, Noise, and Where to Focus Now ↗
Hims & Hers stock is full of noise, but what's the signal for investors? 
Via The Motley Fool
< Previous 1 2
...
30 31 32 33 34 35 36 37 38
...
53 54 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.